Journal of Neural Transmission

, Volume 116, Issue 11, pp 1457–1472

Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain

  • Orly Weinreb
  • Tamar Amit
  • Yotam Sagi
  • Noam Drigues
  • Moussa B. H. Youdim
Basic Neurosciences, Genetics and Immunology - Original Article
  • 272 Downloads

Abstract

The novel anti-Parkinson’s disease (PD) drug, rasagiline (N-propargyl-1-(R)-aminoindan), is a second generation of irreversible selective inhibitor of monoamine oxidase-B follows selegiline. In light of the recent large clinical study (phase III ADAGIO) reporting benefits in PD patients, it has been suggested that rasagiline could be the first PD treatment to receive the label neuroprotective “disease-modifying” drug. Indeed, rasagiline has been shown to have a broad neuroprotective activity against a variety of neurotoxins in preclinical models of neurodegenerative diseases and in cultured neuronal cells. In the present study, we have investigated the status of various molecular and biochemical markers in the rat midbrain following chronic treatments with rasagiline and selegiline, using proteomic and genomic analyses. Our findings demonstrated significant molecular changes induced by both drugs, at the protein and transcriptional levels, associated with neuronal differentiation, cell survival and death pathways, metabolism/oxidation stress, signaling system, and biomarkers of neurodegenerative disorders, which may be reflected in the clinical studies.

Keywords

Parkinson’s disease Rasagiline Selegiline Rat midbrain Genomic and proteomic analyses Neurotrophic factors 

References

  1. Abassi ZA, Binah O, Youdim MBH (2004) Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol 143:371–378CrossRefPubMedGoogle Scholar
  2. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434:109–116CrossRefPubMedGoogle Scholar
  3. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MBH, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and Rasagiline, N-Propargyl-1(R)-aminoindan. J Neurochem 82:913–923CrossRefPubMedGoogle Scholar
  4. Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250CrossRefPubMedGoogle Scholar
  5. Bar-Am O, Amit T, Youdim MBH (2004a) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169–172CrossRefPubMedGoogle Scholar
  6. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MBH (2004b) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 89:1119–1125CrossRefPubMedGoogle Scholar
  7. Bar-Am O, Weinreb O, Amit T, Youdim MB (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19:1899–1901PubMedGoogle Scholar
  8. Bar-Am O, Amit T, Youdim MB (2007) Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 103:500–508CrossRefPubMedGoogle Scholar
  9. Beer I, Barnea E, Ziv T, Admon A (2004) Improving large-scale proteomics by clustering of mass spectrometry data. Proteomics 4:950–960CrossRefPubMedGoogle Scholar
  10. Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in the nervous system. Nat Rev 4:752–762CrossRefGoogle Scholar
  11. Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2004) Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem 47:1767–1774CrossRefPubMedGoogle Scholar
  12. Birkmayer W, Danielczyk W, Neumayer E, Riederer P (1975) Dopaminergic supersensitivity in parkinsonism. Adv Neurol 9:121–129PubMedGoogle Scholar
  13. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with ‘Madopar’ and l-deprenil in Parkinson’s disease: a long-term study. Lancet 1:439–443CrossRefPubMedGoogle Scholar
  14. Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (−)-Deprenyl leads to prolongation of l-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatr 19:170–176Google Scholar
  15. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127CrossRefPubMedGoogle Scholar
  16. Blandini F (2005) Neuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease? CNS Drug Rev 11:183–194PubMedGoogle Scholar
  17. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G (2004) Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp Neurol 187:455–459CrossRefPubMedGoogle Scholar
  18. Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO, Miyasaka K (1996) Long term treatment with (−)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain. Life Sci 59:1047–1057CrossRefPubMedGoogle Scholar
  19. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MBH (2000) Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67:577–585CrossRefPubMedGoogle Scholar
  20. Chen JJ, Ly AV (2006) Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson’s disease. Am J Health Syst Pharm 63:915–928CrossRefPubMedGoogle Scholar
  21. Chen JJ, Swope DM (2005) Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45:878–894CrossRefPubMedGoogle Scholar
  22. Chen JJ, Swope DM, Dashtipour K (2007) Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 29:1825–1849CrossRefPubMedGoogle Scholar
  23. Chuang DM, Ishitani R (1996) A role for GAPDH in apoptosis and neurodegeneration. Nat Med 2:609–610CrossRefPubMedGoogle Scholar
  24. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:P3CrossRefPubMedGoogle Scholar
  25. Ebadi M, Ramana Kumari MV, Hiramatsu M, Hao R, Pfeiffer RF, Rojas P (1998) Metallothionein, neurotrophins and selegiline in providing neuroprotection in Parkinson’s disease. Restor Neurol Neurosci 12:103–111PubMedGoogle Scholar
  26. Ebadi M, Sharma S, Shavali S, El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67:285–289CrossRefPubMedGoogle Scholar
  27. Finberg JP, Youdim MBH (1985) Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol 85:541–546PubMedGoogle Scholar
  28. Finberg JPM, Tenne M, Youdim MBH (1981) Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MBH, Peykel ES (eds) Monoamine oxidase inhibitors—the state of the art. Wiley, Chichester, pp 31–41Google Scholar
  29. Foley P, Gerlach M, Youdim MBH, Riederer P (2000) MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Park Relat Disord 6:25–47CrossRefGoogle Scholar
  30. Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF (2000) The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. NeuroReport 11:3937–3941CrossRefPubMedGoogle Scholar
  31. Grasing K, Azevedo R, Karuppan S, Ghosh S (2001) Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion. Neurochem Res 26:65–74CrossRefPubMedGoogle Scholar
  32. Hu Y, Russek SJ (2008) BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J Neurochem 105:1–17CrossRefPubMedGoogle Scholar
  33. Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya N, Kinoshita M (1994) Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons. J Neurol Sci 125:11–13CrossRefPubMedGoogle Scholar
  34. Kitani K, Minami C, Isobe K, Maehara K, Kanai S, Ivy GO, Carrillo MC (2002) Why (−)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech Ageing Dev 123:1087–1100CrossRefPubMedGoogle Scholar
  35. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408PubMedGoogle Scholar
  36. Kontkanen O, Castren E (1999) Trophic effects of selegiline on cultured dopaminergic neurons. Brain Res 829:190–192CrossRefPubMedGoogle Scholar
  37. Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson’s disease. Lancet 2:791–795CrossRefPubMedGoogle Scholar
  38. LeWitt PA (2004) Clinical trials of neuroprotection for Parkinson’s disease. Neurology 63:S23–S31PubMedGoogle Scholar
  39. Magyar K, Palfi M, Jenei V, Szoko E (2006) Deprenyl: from chemical synthesis to neuroprotection. J Neural Transm Suppl 71:143–156CrossRefPubMedGoogle Scholar
  40. Maruyama W, Naoi M, Kasamatsu T, Hashizume Y, Takahashi T, Kohda K, Dostert P (1997) An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 69:322–329PubMedGoogle Scholar
  41. Maruyama W, Akao Y, Youdim MBH, Naoi M (2000a) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm (Suppl) 60:171–186Google Scholar
  42. Maruyama W, Youdim MBH, Naoi M (2000b) Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, Rasagiline and TV1022. Ann NY Acad Sci 939:320–329Google Scholar
  43. Maruyama W, Akao Y, Carrillo M, Kitani K, Youdium M, Naoi M (2002a) Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24:675–682CrossRefPubMedGoogle Scholar
  44. Maruyama W, Takahashi T, Youdim MBH, Naoi M (2002b) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109:467–481CrossRefPubMedGoogle Scholar
  45. Nadon R, Shoemaker J (2002) Statistical issues with microarrays: processing and analysis. Trends Genet 18:265–271CrossRefPubMedGoogle Scholar
  46. Oakes D (1993) Antiparkinson efficacy of deprenyl. DATATOP Steering Committee of Parkinson Study Group. Ann Neurol 34:634CrossRefPubMedGoogle Scholar
  47. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23:2194–2201CrossRefPubMedGoogle Scholar
  48. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321:176–183Google Scholar
  49. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183CrossRefGoogle Scholar
  50. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59:1937–1943CrossRefGoogle Scholar
  51. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561–566CrossRefGoogle Scholar
  52. Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241–248CrossRefGoogle Scholar
  53. Quackenbush J (2001) Computational analysis of microarray data. Nat Rev Genet 2:418–427CrossRefPubMedGoogle Scholar
  54. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23:324–330CrossRefPubMedGoogle Scholar
  55. Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D (1978) Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (−) deprenyl administration. J Neural Transm 43:271–277CrossRefPubMedGoogle Scholar
  56. Riederer P, Youdim MB, Birkmayer W, Jellinger K (1978a) Monoamine oxidase activity during (−)-deprenil therapy: human brain post-mortem studies. Adv Biochem Psychopharmacol 19:377–382PubMedGoogle Scholar
  57. Riederer P, Youdim MB, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978b) On the mode of action of l-deprenyl in the human central nervous system. J Neural Transm 43:217–226CrossRefPubMedGoogle Scholar
  58. Riederer P, Gille G, Muller T, Przuntek H, Reichmann H, Riess O, Schwartz A, Schwarz J, Vogt T (2002) Practical importance of neuroprotection in Parkinson’s disease. J Neurol 249(Suppl 3):III/53–III/56Google Scholar
  59. Sabbagh A, Youdim MBH (1978) Selective inhibition of monoamine oxidase type B by propargyl-containing drugs. Isr J Med Sci 14:1097Google Scholar
  60. Sagi Y, Mandel S, Y MBH (2003) Genomic and proteomic profiling of the neuroprotective mechanisms of rasagiline in the mouse MPTP model of PD. Neural Plas 10:227Google Scholar
  61. Sagi Y, Mandel S, Amit T, Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced Parkinsonism. Neurobiol Dis 25:35–44CrossRefPubMedGoogle Scholar
  62. Salonen T, Haapalinna A, Heinonen E, Suhonen J, Hervonen A (1996) Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol 91:466–474CrossRefPubMedGoogle Scholar
  63. Semkova I, Wolz P, Schilling M, Krieglstein J (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315:19–30CrossRefPubMedGoogle Scholar
  64. Shen L, Figurov A, Lu B (1997) Recent progress in studies of neurotrophic factors and their clinical implications. J Mol Med (Berlin, Germany) 75:637–644Google Scholar
  65. Shoulson I (1992) An interim report of the effect of selegiline (l-deprenyl) on the progression of disability in early Parkinson’s disease: the Parkinson Study Group. Eur Neurol 32 Suppl 1:46–53CrossRefPubMedGoogle Scholar
  66. Speiser Z, Levy R, Cohen S (1998) Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 52:287–300PubMedGoogle Scholar
  67. Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, Finberg J (1998) (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl 52:301–305PubMedGoogle Scholar
  68. Streifler M, Rabey MJ (1983) Long-term effects of l-deprenyl in chronic levodopa treated parkinsonian patients. J Neural Transm Suppl 19:265–272PubMedGoogle Scholar
  69. Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K (2001) Anti-apoptotic and apoptotic action of (−)-deprenyl and its metabolites. J Neural Transm 108:25–33CrossRefPubMedGoogle Scholar
  70. Tatton WG (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8:S20–S30CrossRefPubMedGoogle Scholar
  71. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1575PubMedCrossRefGoogle Scholar
  72. Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, Pong AW, Tatton NA (2002) Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301:753–764CrossRefPubMedGoogle Scholar
  73. Ting JT, Kelley BG, Sullivan JM (2006) Synaptotagmin IV does not alter excitatory fast synaptic transmission or fusion pore kinetics in mammalian CNS neurons. J Neurosci 26:372–380CrossRefPubMedGoogle Scholar
  74. Weiner M (1982) Update on antiparkinsonian agents. Geriatrics 37(81–84):89–91Google Scholar
  75. Weinreb O, Mandel S, Youdim MBH (2003) Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (−)-epigallocatechine-3-gallate, and melatonin. Ann NY Acad Sci 993:351–361CrossRefPubMedGoogle Scholar
  76. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18:1471–1473PubMedGoogle Scholar
  77. Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC Pathway. Ann NY Acad Sci 1053:348–355CrossRefPubMedGoogle Scholar
  78. Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, Youdim MB (2006) Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl 70:457–465CrossRefPubMedGoogle Scholar
  79. Weinreb O, Drigues N, Sagi Y, Reznick AZ, Amit T, Youdim MB (2007) The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. Antioxid Redox Signal 9:169–179CrossRefPubMedGoogle Scholar
  80. Westermeier R, Marouga R (2005) Protein detection methods in proteomics research. Biosci Rep 25:19–32CrossRefPubMedGoogle Scholar
  81. Yates JR 3rd, Eng JK, McCormack AL, Schieltz D (1995) Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal Chem 67:1426–1436CrossRefPubMedGoogle Scholar
  82. Yogev-Falach M, Amit T, Bar-Am O, Sagi Y, Weinstock M, Youdim MBH (2002) The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16:1674–1676PubMedGoogle Scholar
  83. Yogev-Falach M, Amit T, Bar-AM O, Youdim MBH (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17:2325–2327PubMedGoogle Scholar
  84. Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y (1986) Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16:129–136CrossRefPubMedGoogle Scholar
  85. Youdim MB (2006) The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and M30. Curr Alzheimer Res 3:541–550CrossRefPubMedGoogle Scholar
  86. Youdim MBH, Riederer PF (2004) A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease. Neurology 63:S32–S35PubMedGoogle Scholar
  87. Youdim MB, Tipton KF (2002) Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson’s disease. Parkinsonism Relat Disord 8:247–253CrossRefPubMedGoogle Scholar
  88. Youdim MBH, Finberg JPM, Levy R, Sterling J, Lerner D, Berger-Paskin T, Yallin H (1995) R-Enantiomers of N-propargyl-aminoindan compounds: their preparation and pharmaceutical composition containing them. In: United States Patent. United States, p 133Google Scholar
  89. Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline [N-Propargyl-1R(+)-aminoindant], A selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500–506CrossRefPubMedGoogle Scholar
  90. Youdim MBH, Bar-Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2004) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79:172–179CrossRefGoogle Scholar
  91. Youdim MB, Maruyama W, Naoi M (2005) Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today 41:369–391CrossRefPubMedGoogle Scholar
  92. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, Le W (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105:1970–1978CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Orly Weinreb
    • 1
  • Tamar Amit
    • 1
  • Yotam Sagi
    • 1
  • Noam Drigues
    • 1
  • Moussa B. H. Youdim
    • 1
  1. 1.Department of Pharmacology, Technion-Faculty of Medicine, Rappaport Family Research InstituteEve Topf Centers of Excellence for Neurodegenerative Diseases ResearchHaifaIsrael

Personalised recommendations